Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Landsman, T. Burkey, P. Consroe, W. Roeske, H. Yamamura (1997)
SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.European journal of pharmacology, 334 1
M. Bouaboula, Sylvie Perrachon, L. Milligan, X. Canat, M. Rinaldi-Carmona, M. Portier, F. Barth, B. Calandra, F. Pecceu, J. Lupker, J. Maffrand, G. Fur, P. Casellas (1997)
A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1The Journal of Biological Chemistry, 272
J. Ward, W. Hall, R. Mattick (1999)
Role of maintenance treatment in opioid dependenceThe Lancet, 353
F. Rougé-Pont, V. Deroche, M. Moal, P. Piazza (1998)
Individual differences in stress‐induced dopamine release in the nucleus accumbens are influenced by corticosteroneEuropean Journal of Neuroscience, 10
J. Weidenfeld, S. Feldman, R. Mechoulam (1994)
Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat.Neuroendocrinology, 59 2
E. Nestler, B. Hope, K. Widnell (1993)
Drug addiction: A model for the molecular basis of neural plasticityNeuron, 11
H. Eder, G. Fischer, W. Gombas, R. Jagsch, A. Peternell, Georg Stuhlinger, Harald Aschauer, S. Rasper (1999)
Buprenorphine versus methadone maintenance for the treatment of opioid dependenceEuropean Neuropsychopharmacology, 9
M. Kreek (1997)
Opiate and Cocaine Addictions: Challenge for PharmacotherapiesPharmacology Biochemistry and Behavior, 57
M. Martellotta, G. Cossu, L. Fattore, G. Gessa, Walter Fratta (1998)
Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive miceNeuroscience, 85
E. Valjent, R. Maldonado (2000)
A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice.Psychopharmacology, 147 4
A. Herz, T. Shippenberg (1992)
Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.Proceedings of the National Academy of Sciences of the United States of America, 89 6
The CCK - B antagonist PD - 134 , 308 facilitates rewarding e ects of endogenous enkephalins but does not induce place preference in rats
A. Zimmer, A. Zimmer, A. Hohmann, M. Herkenham, T. Bonner (1999)
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.Proceedings of the National Academy of Sciences of the United States of America, 96 10
P. Smith, S. Welch, B. Martin (1994)
Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice.The Journal of pharmacology and experimental therapeutics, 268 3
MALDONADO (1995)
Protein kinases in the locus coeruleus and periaqueductal gray matter are involved in the expression of opiate withdrawalNaunyn-Schmiedberg's Arch. Pharmacol., 352
VALVERDE (1996b)
Protein kinases in the rat nucleus accumbens are involved in the aversive component of opiate withdrawalEur. J. Pharmacol., 8
D. Piomelli, A. Giuffrida, A. Calignano, F. Fonseca (2000)
The endocannabinoid system as a target for therapeutic drugs.Trends in pharmacological sciences, 21 6
K. Dyer, D. Foster, J. White, A. Somogyi, A. Menelaou, F. Bochner (1999)
Steady‐state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration‐effect relationshipsClinical Pharmacology & Therapeutics, 65
Miles Herkenham, B. Groen, A. Lynn, B. Costa, E. Richfield (1991)
Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellumBrain Research, 552
C. Felipe, J. Herrero, J. O'Brien, J. Palmer, C. Doyle, Andrew Smith, J. Laird, C. Belmonte, F. Cerveró, S. Hunt (1998)
Altered nociception, analgesia and aggression in mice lacking the receptor for substance PNature, 392
R. Mansbach, K. Nicholson, Martin Br, R. Balster (1994)
Failure of Δ9‐tetrahydrocannabinol and CP 55,940 to maintain intravenous self‐administration under a fixed‐interval schedule in rhesus monkeysBehavioural Pharmacology, 5
M. Navarro, J. Chowen, M. Carrera, I. Arco, M. Villanúa, Yolanda Martin, A. Roberts, G. Koob, F. Fonseca (1998)
CB1 cannabinoid receptor antagonist‐induced opiate withdrawal in morphine‐dependent ratsNeuroReport, 9
S. Welch (1997)
Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems.Drug and alcohol dependence, 45 1-2
Y. Shaham, S. Erb, Shirley Leung, Y. Buczek, J. Stewart (1998)
CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained ratsPsychopharmacology, 137
O. Valverde, E. Tzavara, J. Hanoune, B. Roques, R. Maldonado (1996)
Protein Kinases in the Rat Nucleus Accumbens are Involved in the Aversive Component of Opiate WithdrawalEuropean Journal of Neuroscience, 8
J. Manzanares, J. Corchero, J. Romero, J. Fernández-Ruiz, J. Ramos, J. Fuentes (1999)
Pharmacological and biochemical interactions between opioids and cannabinoids.Trends in pharmacological sciences, 20 7
D. Hutcheson, E. Tzavara, C. Smadja, E. Valjent, B. Roques, J. Hanoune, R. Maldonado (1998)
Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with Δ‐9‐tetrahydrocannabinolBritish Journal of Pharmacology, 125
Laurie Punch, D. Self, E. Nestler, JaneR Taylor (1997)
Opposite Modulation of Opiate Withdrawal Behaviors on Microinfusion of a Protein Kinase A Inhibitor Versus Activator into the Locus Coeruleus or Periaqueductal GrayThe Journal of Neuroscience, 17
M. Rinaldi-Carmona, F. Barth, M. Héaulme, D. Shire, B. Calandra, C. Congy, Serge Martinez, J. Maruani, G. Néliat, D. Caput, P. Ferrara, P. Soubrié, J. Breliere, G. Fur (1994)
SR141716A, a potent and selective antagonist of the brain cannabinoid receptorFEBS Letters, 350
E. Valjent, Rafael Maldonado (2000)
A behavioural model to reveal place preference to Δ9-tetrahydrocannabinol in micePsychopharmacology, 147
B. Senault (1976)
[Aggressive behaviour induced by apomorphine: relations with some elements of the behavioural profile and with the sensitivity to apomorphine (author's transl)].Psychopharmacology, 48 1
G. Fischer, W. Gombas, H. Eder, R. Jagsch, A. Peternell, Georg Stuhlinger, L. Pezawas, H. Aschauer, S. Kasper (1999)
Buprenorphine versus methadone maintenance for the treatment of opioid dependence.Addiction, 94
A. Kuzmin, S. Semenova, M. Gerrits, E. Zvartau, J. Ree (1997)
κ-Opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and miceEuropean Journal of Pharmacology, 321
I. Meng, B. Manning, W. Martin, H. Fields (1998)
An analgesia circuit activated by cannabinoidsNature, 395
HARRIS (1974)
Evaluation of reinforcing capability of delta-9-tetrahydrocannabinol in rhesus monkeysPsychopharmacologia, 37
R. Steinpreis, Aaron Rutell, Folafemi Parrett (1996)
Methadone produces conditioned place preference in the ratPharmacology Biochemistry and Behavior, 54
C. Ledent, O. Valverde, G. Cossu, F. Petitet, J. Aubert, F. Beslot, G. Böhme, A. Imperato, T. Pedrazzini, B. Roques, G. Vassart, W. Fratta, M. Parmentier (1999)
Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.Science, 283 5400
G. Tanda, F. Pontieri, G. Chiara (1997)
Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.Science, 276 5321
H. Matthes, R. Maldonado, F. Simonin, O. Valverde, S. Slowe, I. Kitchen, K. Befort, A. Dierich, M. Meur, P. Dollé, E. Tzavara, J. Hanoune, B. Roques, B. Kieffer (1996)
Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor geneNature, 383
M. Lepore, Stanislav Vorel, J. Lowinson, E. Gardner (1995)
Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward.Life sciences, 56 23-24
SPANAGEL (1992)
Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathwayProc. Natl. Acad. Sci. U.S.A., 89
G. Chiara, A. Imperato (1988)
Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.The Journal of pharmacology and experimental therapeutics, 244 3
(1975)
Tolerance to the eects of delta-9-tetrahydrocannabinol in mice on intestinal motility, temperature and locomotor activity
LEITE (1974)
Failure to obtain “cannabis-directed behavior” and abstinence syndrome in rats chronically treated with Cannabis sativa extractsPsychopharmacology, 36
Stacie Cook, J. Lowe, Billy Martin (1998)
CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.The Journal of pharmacology and experimental therapeutics, 285 3
S. Welch, C. Thomas, G. Patrick (1995)
Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine.The Journal of pharmacology and experimental therapeutics, 272 1
G. Koob, M. Moal (1997)
Drug abuse: hedonic homeostatic dysregulation.Science, 278 5335
Andreas Zimmer, A. Zimmer, Judith Baffi, Ted Usdin, Kay Reynolds, Monika Konig, Miklós Palkovits, Eva Mezey (1998)
Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene.Proceedings of the National Academy of Sciences of the United States of America, 95 5
E. Ambrosio, Sonsoles Martı́n, C. Garcı́a-Lecumberri, J. Crespo (1999)
The neurobiology of cannabinoid dependence: sex differences and potential interactions between cannabinoid and opioid systems.Life sciences, 65 6-7
C. Vásquez, D. Lewis (1999)
The CB1 Cannabinoid Receptor Can Sequester G-Proteins, Making Them Unavailable to Couple to Other ReceptorsThe Journal of Neuroscience, 19
A. Lichtman, Billy Martin (1991)
Spinal and supraspinal components of cannabinoid-induced antinociception.The Journal of pharmacology and experimental therapeutics, 258 2
James Kuhlman, Barry Levine, Rolley Johnson, P. Fudala, E. Cone (1998)
Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine.Addiction, 93 4
W. Dewey (1986)
Cannabinoid pharmacology.Pharmacological reviews, 38 2
L. Swanson, P. Sawchenko, J. Rivier, W. Vale (1983)
Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study.Neuroendocrinology, 36 3
Several compounds, mainly opioid agonists such as methadone, are currently used for long term medication of heroin addicts. Nevertheless, these maintenance treatments have the disadvantage to induce a dependence to another opiate. As interactions between opioid and cannabinoid systems have been demonstrated, the ability of the CB1 antagonist, SR141716A to reduce morphine‐induced addiction was investigated. The effects of SR141716A on the rewarding responses of morphine were evaluated in the place conditioning paradigm. No significant conditioned preference or aversion were observed after repeated treatment with the CB1 antagonist alone. However, SR141716A was able to antagonize the acquisition of morphine‐induced conditioned place preference. SR141716A was co‐administered with morphine for 5 days, and the withdrawal syndrome was precipitated by naloxone administration. A reduction in the incidence of two main signs of abstinence: wet dog shakes and jumping was observed while the other were not significantly modified. In contrast, an acute injection of the CB1 antagonist just before naloxone administration was unable to modify the incidence of the behavioural manifestations of the withdrawal, suggesting that only chronic blockade of CB1 receptors is able to reduce morphine‐induced physical dependence. Several biochemical mechanisms could explain the reduction of opioid dependence by CB1 antagonists. Whatever the hypotheses, this study supports the reported interaction between the endogenous cannabinoid and opioid systems, and suggests that SR 141716A warrants further investigations for a possible use in opioid addiction. British Journal of Pharmacology (2001) 132, 1809–1816; doi:10.1038/sj.bjp.0703990
British Journal of Pharmacology – Wiley
Published: Apr 1, 2001
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.